Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value US$0.001 per share, offered at a price of US$28.50 per share, before underwriting discounts. The offering is expected to close on or about January 5, 2024, subject to customary closing conditions. Gross offering proceeds will be approximately US$450.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Latham & Watkins LLP represents the underwriters in the offering, with a capital markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Peter Simon, Brian Daley, and Sterling Swift.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
